Loading company…
Guangdong biotech developing innovative drugs for respiratory and metabolic diseases, and a subsidiary of Zhongsheng Pharma.
Based in Guangdong, China and founded in 2018, Guangdong Raynovent Biotech Co., Ltd., doing business as Raynovent, researches and commercializes innovative drugs for diseases including influenza, primary biliary cholangitis, NASH and avian influenza. It was formed by and operates as a subsidiary of Zhongsheng Pharma, which is listed on the Shenzhen Stock Exchange. Founder Chaofeng Long holds a master's degree in clinical pharmacology from Beijing Medical University. In August 2026 Zhongsheng Pharma announced it would acquire a 12.06% minority stake from Lake Bleu Capital, Snow Owl, LLC and BioTrack Capital for over USD 28.26 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in